CARBOCYSTEINE LYSINE SALT MONOHYDRATE IN TREATMENT OF DISEASES OF LOWER RESPIRATORY TRACT IN CHILDREN
https://doi.org/10.15690/vsp.v12i6.889
Abstract
Inflammatory diseases of the respiratory tract are characterized by changes in rheological properties of the phlegm and lower of the mucociliary clearance. Adjustment of mucoregulatory agents is of a special significance in treatment of diseases of the lower respiratory tract in children. Aim: to assess efficacy of carbocysteine lysine salt monohydrate as a mucokinetic agent in children with respiratory tract diseases. Patients and methods: 65 children (31 girls and 34 boys) aged from 5 to 16 years old with acute respiratory tract diseases received treatment in Belgorod pediatric out-patient clinic № 4 were included into the study. The results of the clinical follow-up of these children are shown in the article. Results: carbocysteine lysine salt monohydrate was found to be effective and safe in treatment of acute and chronic inflammatory diseases of the respiratory tract in children. The authors observed quicker convalescence of the patients and possibility of combination of this drug with other medicines used in pediatric practice. Conclusions: the above-mentioned drug when used in combination with antibacterial agents intensifies penetration of the latter into the bronchial secretion and bronchial mucous membrane thereby increasing their efficacy. The drug does not have toxicity, is well-tolerated even when prolonged using and can be recommended for treatment of cough in children both under out- and in-patients conditions.
Keywords: children, respiratory tract diseases, carbocysteine.
About the Author
T. A. Kruchkova
Belgorod State National Research University
Russian Federation
Kryuchkova Tatyana Alekseevna, Candidate of Medical Science, Assistant Professor of Pediatrics for the course of children’s surgical diseases
Russian Federation
Kryuchkova Tatyana Alekseevna, Candidate of Medical Science, Assistant Professor of Pediatrics for the course of children’s surgical diseases
References
1. Mizernitskiy Yu. L., Ermakova I. N. Sovremennye mukoaktivnye preparaty v terapii ostrykh respiratornykh zabolevaniy u detey [Modern mucoactive drugs in the treatment of acute respiratory infections in children]. Consilium medicum (Pediatriya) — Consilium medicum (Pediatrics). 2007; 09 (1): 53–56.
2. Bogdanova A. V. Effektivnost preparata Fluifort v lechenii retsidiviruyushchego i khronicheskogo bronkhitov u detey [The effectiveness of Fluifort in the treatment of recurrent and chronic bronchitis in children]. Pulmonologiya detskogo vozrasta: problemy i resheniya — Pediatric pulmonology: Problems and solutions. 2005; 5: 77–79.
3. Zaytseva O. V., Bardenikova S. I., Zaytseva S. V., Rychkova T. I., Lokshina E. E. Sovremennye aspekty patogeneticheskoy terapii kashlya u detey [Modern aspects of pathogenetic therapy of cough in children]. Lechashchiy vrach [Attending doctor]. 2010; 2: http://www. lvrach.ru/2010/02/12158998/.
4. Mizernitskiy Yu. L., Melnikova I. M., Batozhargalova B.Ts., Loginevskaya Ya. V. Sovremennaya mukoaktivnaya terapiya u detey s ostrymi i khronicheskimi bronkholegochnymi zabolevaniyami [Modern mucoactive therapy in children with acute and chronic bronchopulmonary diseases]. RMZh. Mat i ditya. Pediatriya — RMJ. Mother and child. Pediatrics. 2011; 19 (3): 150–155.
5. Tatochenko V. K. Prakticheskaya pulmonologiya detskogo vozrasta (spravochnik) [Practical pediatric pulmonology (handbook)]. Moscow, 2000.
6. Volkov I. K., Davydova I. V., Kulichikhin V. G., Lukina O. F. Novye vozmozhnosti mukoliticheskoy terapii pri khronicheskikh i retsidiviruyushchikh zabolevaniyakh legkikh u detey [New opportunities for mucolytic therapy for chronic or recurrent lung diseases in children]. Consilium Medicum (Pulmonologiya) — Consilium Medicum (Pulmonology). 2006; 8 (1): http://www.consilium-medicum. com/pylmo/article/9559/.
7. Kosenko I. M. O ratsionalnom vybore farmakoterapii pri zabolevaniyakh, soprovozhdayushchikhsya kashlem [On the rational choice of pharmacotherapy for diseases accompanied by cough]. Consilium Medicum (Pediatriya) — Consilium medicum (Pediatrics). 2010; 3: 33–40.
8. Mizernitskiy Yu. L., Melnikova I. M., Batozhargalova B.Ts., Logi ne vskaya Ya. V., Kozlova L. V. Mukoliticheskaya terapiya pri zaboleva niyakh nizhnikh dykhatelnykh putey [Mucolytic therapy for diseases of the lower respiratory tract]. Vrach [Doctor]. 2009; 12: 78–82.
9. Duijvestijn Y. C., Mourdi N., Smucny J., Pons G., Chalumeau M. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochr. Database Syst. Rev. 2009; 1: CD003124.
10. Ishiura Y., Fujimura M., Yamamori C., Nobata K., Myou S., Kurashima K., Michishita Y., Takegoshi T. Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients. Division of Pulmonarу Medicine, Wajima Municipal Hospital, Wajima, Japan. Brit. J. Clin. Pharmacol. 2003; 55 (6): 504.
11. Maccio A., Madeddu C., Panzone F., Mantovani G. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Exp. Opin. Pharmacother. 2009; 4: 693–703.
Review
For citations:
Kruchkova T.A. CARBOCYSTEINE LYSINE SALT MONOHYDRATE IN TREATMENT OF DISEASES OF LOWER RESPIRATORY TRACT IN CHILDREN. Current Pediatrics. 2013;12(6):136-139. (In Russ.) https://doi.org/10.15690/vsp.v12i6.889
Views:
5088
Email this article 
